Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)

CONCLUSIONS: V114 is well tolerated with a consistent safety profile and immune response across manufacturing lots.CLINICAL TRIALS REGISTRATION: NCT03950856 (www.clinicaltrials.gov); 2018-004266-33 (EudraCT).PMID:35039194 | DOI:10.1016/j.vaccine.2021.12.067

Source: Vaccine - January 18, 2022 Category: Allergy & Immunology Authors: Jakub K Simon Nina Breinholt Staerke Maria Hemming-Harlo Stacey Layle Ron Dagan Tulin Shekar Alison Pedley Patricia Jumes Gretchen Tamms Tina Sterling Luwy Musey Ulrike K Buchwald V114-020 PNEU-TRUE study group Source Type: research